 |
Business Wire - July 26, 2005
"Due to its oral delivery, higher antiviral activity and greater antiviral activity against drug resistant virus, Thiovir continues to show promise as an alternative to foscarnet, which is an effective antiviral, but has limited use due to its toxicity and inconvenient delivery by protracted intravenous administration," said Joan M. Robbins, Ph.D., ADVENTRX chief technical officer and co-author of the study.
"In combination testing with zidovudine, an NRTI, Thiovir was highly synergistic, while foscarnet was only slightly synergistic to antagonistic. This has important clinical implications as suitable drug regimens combining Thiovir with an NRTI could allow for decreased drug dosage," added Dr. Robbins.
The poster "Anti-HIV-1 Activity of a Foscarnet Analogue, Synergy with Zidovudine and Analysis of Resistance Variants Selected in Vitro" was presented by ADVENTRX senior scientist Shani Waninger, Ph.D. Copies of the poster are available on the "Resource Library" section of the Company's Web site at www.adventrx.com .
About Thiovir
Thiovir is a non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for oral delivery as a component of AZT-based highly active antiretroviral therapy (HAART). Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet) in an oral formulation. Thiovir is intended to deliver all of the benefits of the FDA-approved drug foscarnet, including broad spectrum antiviral activity, with the added benefit of improved cell permeability. ADVENTRX currently plans to file an investigational new drug application with the US Food and Drug Administration in the first quarter of 2006.
About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability or resistance. The Company's lead compound, CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor is currently being tested with 5-FU in a US-based Phase II and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor has received clearance under a special protocol assessment from the US Food and Drug Administration to begin a Phase III pivotal clinical trial for metastatic colorectal cancer. More information can be found on the Company's Web site at www.adventrx.com .
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the U.S. Food and Drug Administration (FDA) and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's last quarterly report on Form 10-Q, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
CONTACT: ADVENTRX Pharmaceuticals
Andrea Lynn, 858-552-0866
or
Investor Contact:
Lippert/Heilshorn & Associates
Jody Cain/Brandi Floberg, 310-691-7100
jcain@lhai.com / bfloberg@lhai.com
SOURCE: ADVENTRX Pharmaceuticals, Inc.
050726
BW050709
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .